Vistagen jumps after Citadel founder Ken Griffin discloses stake

Vistagen Therapeutics

16/10/2023 22:08

** Shares of Vistagen Therapeutics Inc  VTGN.O  jump 12% to
$3.55 post-market after Citadel founder Ken Griffin reveals
stake
    ** Griffin reports owning ~1.59 mln VTGN shares for 5.7%
passive stake, per SEC filing
    ** On Oct 2, Vistagen announced it priced $100 mln
stock-and-warrants offering at $5.38
    ** That financing was led by BVF Partners with participation
from Citadel company Surveyor Capital, among other institutional
investors
    ** Griffin's stake based on ~27.8 mln VTGN shares
outstanding, per filing on Mon
    ** On Aug 7, VTGN's stock skyrocketed nearly 8-fold to close
at $13.05 after its nasal spray, fasedienol, for adults
diagnosed with social anxiety disorder met main goal in late
stage study
    ** VTGN's shares finished 2021 at $58.50 and ended 2022 at
$3.09 

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-646-279-6380))